CRIS trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CRIS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 18 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Curis, Inc. (CRIS) has a Wall Street consensus price target of N/A, based on estimates from 18 covering analysts. The company has a market capitalization of $2M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 16 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CRIS trades at a trailing P/E of -0.1x. Analysts expect EPS to grow +84.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 TGTXTG Therapeutics, Inc. | $8.6B | $56.00 | $80.50 | +43.8% | Buy | 55.8x | 13 |
 KPTIKaryopharm Therapeutics Inc. | $40M | $1.75 | $14.17 | +709.7% | Buy | — | 20 |
 MGNXMacroGenics, Inc. | $242M | $3.80 | $6.00 | +57.9% | Buy | — | 22 |
 IMVTImmunovant, Inc. | $7.1B | $34.54 | $40.00 | +15.8% | Buy | — | 23 |
 PRTAProthena Corporation plc | $454M | $8.68 | $30.00 | +245.6% | Buy | 78.9x | 28 |
 PTCTPTC Therapeutics, Inc. | $5.2B | $62.34 | $105.13 | +68.6% | Buy | 49.1x | 26 |
 FATEFate Therapeutics, Inc. | $283M | $2.43 | $5.63 | +131.7% | Buy | — | 31 |
 AGENAgenus Inc. | $350M | $8.40 | $25.00 | +197.6% | Buy | 10.8x | 11 |
 INVAInnoviva, Inc. | $1.5B | $20.24 | $38.00 | +87.7% | Buy | 8.2x | 10 |
 RCUSArcus Biosciences, Inc. | $3.3B | $26.39 | $40.00 | +51.6% | Buy | — | 18 |
Quick answers to the most common questions about buying CRIS stock.
The consensus price target for CRIS is $N/A, close to the current price of $0.9519 (N/A% implied move). Based on 18 analyst estimates, the stock appears fairly valued near current levels.
CRIS has a consensus rating of "Buy" based on 18 Wall Street analysts. The rating breakdown is predominantly bullish, with 16 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
CRIS's current price is $0.9519 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for CRIS, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
CRIS is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 16 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CRIS stock forecast based on 18 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
CRIS appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CRIS analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.